Ovarian Cancer :: Hormone therapy offers new hope for ovarian cancer patients
Researchers at the University of Edinburgh have shown that hormone therapy can extend life in ovarian cancer patients, giving women a new alternative to chemotherapy.
Ovarian cancer
Ovarian Cancer :: First US Consensus on Ovarian Cancer Symptoms
The National Ovarian Cancer Coalition (NOCC) joins the Gynecologic Cancer Foundation and other national organizations in announcing the first national agreement on ovarian cancer symptoms. Often referred to as the ?silent killer? due to the common belief that there are no warning signs or symptoms, ovarian cancer is the most deadly reproductive cancer.
Cancer :: ChemGenex reports successful personalized dosing of Quinamed at ASCO
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced the presentation of data from its Quinamed? (amonafide dihydrochloride) phase 1/2a dose-escalation study, designed to identify a genotypically optimised dose of Quinamed in heavily pre-treated patients with a variety of solid tumors.
Melanoma :: Phase II study shows combination improves survival of metastatic melanoma patients
Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma.
Ovarian Cancer :: VEGF Trap shows activity in patients with advanced ovarian cancer
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.
Breast Cancer :: Possible new breast cancer gene
Researchers at the Abramson Family Cancer Research Institute of the University of Pennsylvania and the Dana-Farber Cancer Institute describe in this week?s issue of Science a new candidate breast-cancer susceptibility gene. The Rap80 gene is required for the normal DNA-repair function of the well-known breast cancer gene BRCA1.
Gene :: Gene thought to assist chemo may help cancer thrive
A gene thought to be essential in helping chemotherapy kill cancer cells, may actually help them thrive. In a new study of chemo patients, scientists at the Georgia Institute of Technology and the Ovarian Cancer Institute found that 70 percent of subjects whose tumors had mutations in the gene p53 were still alive after five years. Patients with normal p53 displayed only a 30 percent survival rate.
Cancer :: Dealing deadly cancers a knockout punch
New scientific evidence is helping to build a compelling case for oncolytic viruses as a first-line and adjunctive treatment for many cancers. Reovirus, a non-pathogenic virus under development at Calgary, Alberta-based Oncolytics Biotech, has shown powerful anti-cancer activity against cultured tumor cells, in animal models, and in human clinical trials. Oncolytics’ proprietary reovirus formulation, Reolysin?, is active against numerous cancers, including intractable sarcomas and melanomas.
Ovarian Cancer :: Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer
A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.
Chemotherapy :: Diabetes drug dramatically boosts power of platinum chemotherapy
A widely used diabetes drug dramatically boosted the potency of platinum-based cancer drugs when administered together to a variety of cancer cell lines and to mice with tumors, scientists from Dana-Farber Cancer Institute report.